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Background: Lipids A, the lipophilic partial structure of lipopolysaccharides, induce regression of several tumor
types in animal models. Rather than exerting direct cytotoxic effect, these compounds trigger the immune system
which in turn stimulates secretion of cytokines, and activates the inducible nitric oxide synthase, as well as immune
cell infiltration of tumors. OM-174 is an analogue of lipid A with dual action on Toll-like receptors 2 and 4. In an
experimental model of peritoneal carcinomatosis induced in BDIX rats by intraperitoneal injection of syngeneic
PROb colon cancer cells, it induced a complete regression of tumors. The present phase I trial was conducted to
determine the maximum tolerated dose, the recommended phase II dose and biological response associated with
OM-174 administered as intravenous infusion.
Methods: Patients received OM-174 twice weekly for a total of 5, 10 or 15 injections of either 600, 800 or 1000 μg/m2.
Blood samples for pharmacokinetic analysis and cytokine dosages were collected. NK cells activity and Toll-like
receptors 4 polymorphism analysis were also performed.
Results: Seventeen patients were included. The highest dose administered was 1000 μg/m2 repeated in 15 injections.
The most common toxicities were a chills, fever, nausea/vomiting, diarrhea, fatigue and headache. No patient
experienced haematological side effects. As no dose limiting toxicity was observed, despite a grade 3 respiratory
complication, the maximal tolerated dose and recommended dose were not established. Three patients exhibited
disease stabilization with a mean duration of 4 months. Pharmacokinetic profile of OM-174 was characterized by a low
distribution volume and clearance. Analysis of TLR 4 polymorphysm showed that most (16/17) patients carried the wild
type alleles. A progressive increase in NK cell number and activity was observed only in patients receiving 1000 μg/m2
of OM-174. A peak of IL-8 and IL-10 concentrations were observed after each OM-174 injection. Peaks of TNF-alpha and
IL-6 concentrations were detected after the first infusion and decreased progressively suggesting tolerance.
Conclusion: OM-174 therapy was well tolerated at biologically active concentrations. Whereas the recommended dose
was not determined, further studies are planned in combination with chemotherapy as animal models suggest a
strong synergistic antitumor effect.
Trial registration: NCT01800812 (ClinicalTrials.gov Identifier).
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Despite a downward trend of mortality rates [1-5], cancer
remains the second cause of death, after cardiovascular
diseases, in industrialized countries accounting for
570,000 deaths in the USA in 2010 [6,7].
Whereas the primary tumor can, in most cases, be
efficiently treated by a combined therapeutic approach,
preventing the metastatic spread of the disease is often
not effective. The eradication of disseminated tumor cells
present in the blood circulation and micro-metastases in
distant organs therefore represents another promising
approach of cancer immunotherapy. The immune system
could recognize tumor-specific antigens, and eliminate
cancer cells. Furthermore it has been highlighted that
some cancers, such as colorectal cancer, cause direct
inhibition of the host's immune response with a detrimental
effect upon prognosis suggesting that stimulation of the
immune system might offer a therapeutic strategy to
counteract these effects [8]. This has been observed with
Toll-like receptor 2 (TLR2), TLR4 and TLR9 agonists,
such as BCG and paclitaxel, which have demonstrated
significant benefit for the treatment of bladder and breast
cancers [9-11].
Toll-like receptors (TLRs) are important sensors of
foreign microbial components as well as products of
damaged or inflamed self-tissues. TLRs are a family
of type I transmembrane proteins that are the major
pattern recognition receptors, and using TLR proteins,
host can recognize the conserved molecular structures
found in pathogens called pathogen-associated molecular
patterns (PAMPs). In addition to their recognition of
PAMPs, several TLRs have also been shown to recognize
endogenous ligands associated with inflammation, which
have been termed danger-associated molecular pat-
terns (DAMPs). Then, TLRs have an important role in
maintaining tissue homeostasis by regulating the in-
flammatory and tissue repair in responses to injury.
There are 13 TLRs described in mammals with a broad
expression profile but TLR11, 12 and 13 are not expressed
in the human genome. TLR1, TLR2, TLR4, TLR5 and
TLR6 reside in the plasma membrane and recognize extra-
cellular ligands [12]. It is now well recognized that TLR4 is
signalling receptor for lipopolysaccharides (LPS) and more
specifically lipid A [13,14].
LPS are major cell wall components of Gram-negative
bacteria and were found to be able to induce regression
of several tumor types in animal models [15]. This
antitumor activity is related to lipids A, a component
of LPS with oligosaccharide core and polysaccharide
chain [16-19]. Lipids A do not induce direct cytotoxicity
on tumor cells but trigger the immune system [16,19]
stimulating expression and secretion of several cyto-
kines [20,21], and activating the inducible nitric oxide
synthase (NOSII) [22]. They also induce activation ofvarious immune cells which infiltrate the tumors
[15,17,23,24].
OM-174 is an analogue of lipid A that exerts, in
experimental models, anti-tumoral effect against different
tumor types including colon and breast cancers and
melanoma [17,25]. In a model of peritoneal carcinomatosis
induced in BDIX rats by intraperitoneal injection of
syngeneic PROb colon cancer cells, intravenous (IV)
administration of OM-174 (1 mg/kg, 15 times every
third day), induced complete regression of tumors and
hemorrhagic ascitis in 95% of cases [17]. This anti tu-
moral activity was associated with cytokine secretion
and NOSII activation [22].
Based on these experimental data showing that several
administrations are needed to achieve antitumor effect,
as well as on the overall favourable safety profile of lipid A
analogues observed in phase I studies [26-28] including
two with single IV-administration of OM-174, one
conducted in healthy volunteers and the other in patients
with solid cancer, we designed a phase I study with
repeated dose of OM-174. The aim of this study was to
determine tolerability, toxicities, the maximum tolerated
dose (MTD) based upon predetermined dose limiting
toxicities (DLT) and the recommended phase II dose of
OM-174 administered as a 15 minutes intravenous infu-
sion, repeated twice weekly for 5, 10 or 15 administrations.
This new phase one was deemed necessary as animal
data suggested that repeated administration of OM-174
were needed to observe anti-tumor effect, with a maximal
effect observed after 15 injections. This study also aimed
to assess the pharmacokinetic profile and the biological
response induced by OM-174 in the multidose adminis-
tration schedule.
Methods
This was a single center phase I study conducted in the
clinical research unit (Centre Georges-François Leclerc -
INSERM CIC-P 803) in Dijon France. The study protocol
and its amendments were approved by Ethics Committee
and Health Authorities (NCT01800812 (ClinicalTrials.gov
Identifier)). The trial was designed according to the
current Declaration of Helsinki [29] and conducted in
accordance with Good Clinical Practice Guidelines.
Written informed consent was obtained from each
participating patient before study entry. The study was
supported by a grant from the French Ministry of health
(Projet Hospitalier de Recherche Clinique, PHRC 2002).
OM-174 was a generous gift from OM-Pharma (Geneva,
Switzerland).
Patients selection
Patients were eligible if they were ≥ 18 years, had
histologically proven metastatic solid tumor with meas-
urable progressive disease outside the central nervous













1 5 600 μg/m2 3 15
2 10 600 μg/m2 3 30
3 15 600 μg/m2 3 36
4 5 800 μg/m2 3 15
5 10 800 μg/m2 3 17
6 15 800 μg/m2 0 0
7 5 1000 μg/m2 0 0
8 10 1000 μg/m2 2 25
9 15 1000 μg/m2 0 0
Suppression of dose level 6 and 7 after amendment of the protocol.
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Other requirements included predicted life expectancy ≥ 3
months; a WHO performance status (PS) ≤ 2, no severe
or uncontrolled medical conditions; adequate hematologic
count), no severe liver impairment and adequate renal
function according to international standard values.
Patients must have recovered from adverse events due
to agents administered > 4 weeks earlier or ≥ 6 weeks
for nitro urea or mitomycine C.
Main non-inclusion criteria were medical history of
cardiac disorders; medical history of auto immune disease
and corticosteroids use.
Study design and dose escalation scheme
Based on animal models suggesting that maximal
anti-tumoral was achieved with 15 infusions it was
decided to include the number (Nb) of infusions in the
definition of Dose Levels to confirm the good tolerance of
a growing number of OM-174 injections. A standard
phase I design was thus used with 3 to 6 patients to be
included per each OM-174 infusion dose level (DL: 600,
800 and 1000 μg/m2) and each number of infusions
(5, 10, 15). Patients were observed for the first 2 weeks
before the next dose escalation was deemed possible. The
MTD was defined as the DL at which two or more out of
3 or 6 patients of a DL developed a dose-limiting toxicity
(DLT). The recommended dose (RD) for further clinical
testing, defined as the DL below the MTD, had to be
assessed in at least 6 patients.
Dose Limiting Toxicities (DLTs)
DLTs were defined using the Common Terminology
Criteria for Adverse Events version 2.0 (CTCAE) as any
of the following events deemed attributable to OM-174,
i.e. occurring during the time of the deliverance of this
drug and a follow-up period of 30 days: Grade 4 neutro-
penia lasting 5 or more consecutive days; febrile neutro-
penia; neutropenic infection; Grade 4 thrombocytopenia
or Grade 3 thrombocytopenia with bleeding requiring
platelet transfusion; Grade 4 anaemia, any Grade 3 or
greater drug related non haematological toxicity (except
nausea, vomiting, alopecia).
Study drug administration
In this open-label, nonrandomised phase I study, with
double dose escalation protocol, OM-174 was administered
intravenously as a 15 minutes infusion twice weekly at
repeated intervals of 3 and 4 days. OM-174 was
manufactured by OM Pharma Pharmaceuticals, Inc
(Geneva, Switzerland).
Based on the results of a previous unpublished phase I
study of single administration of OM-174 to cancer patients
where only one serious adverse event, a severe transient
hypoxia, occurred at the dose level of 800 μg/m2,with no other safety concerns with OM-174 dose up
to 1300 μg/m2, it was decided that all patients would have
to receive a first administration of 600 μg/m2 to reduce
the risk of severe reaction. The dose escalation protocol
and the dose levels are depicted in Table 1.
Pre-treatment evaluation and follow up
At baseline, physical examination and routine labora-
tory tests were performed and WHO PS determined.
Complete blood cell count was obtained on a weekly
basis. Biochemical profile was performed at inclusion
and each drug administration. All toxicities were graded
using the CTCAE version 2.0. Each patient had to
receive the full course of treatment, except in case of
early progression, unacceptable toxicity, serious inter-
current illness, or patient refusal. Tumor measurements
were performed at baseline, at the end of the treatment
(i.e 3, 5 and 8 weeks after the beginning of treatment in
the cohorts with 5, 10 and 15 infusions respectively).
In case of control of disease, tumor assessment was
performed on a monthly basis. Responses were assessed
using RECIST [30].
Pharmacokinetic assessment
Blood samples for pharmacokinetic (PK) of OM-174
were drawn at pre-dose, 1 h, 2 h, 4 h, 24 h for the first
infusion and at pre-dose, 1 and 2 h for the 2nd, 3rd, 5th,
9th and 15th infusions, when appropriate. For all other
interim injections, two blood samples were collected,
before and at the end of IV-infusion.
PK parameters assessed were Cmax, Tmax, area under
the curve (AUC) Last, and AUC0-inf., systemic clearance
(Cl), volume of distribution (Vdβ) and elimination half-life
(t1/2_lambda_z).
Cytokines measurement
Blood samples were collected for cytokine dosage
(IL-1β, IL-6, IL-8, IL-10, IL-12, TNF-α) at the same
Table 2 Patient’s characteristics
Characteristic Nb of patient (%)
Nb of registered and treated patients 17
Age (years)
Median 59









Colon or colorectal cancer 7 (41%)
Breast cancer 5 (29%)
Ovarian cancer 2 (12%)
Non-small-cell-lung cancer 1 (6%)












Adrenal gland 1 (6%)
Previous lines of chemotherapy
Median 5
Range 1 - 11
Distance by last chemotherapy
Median (months) 1,5
Range 1 - 18
Isambert et al. BMC Cancer 2013, 13:172 Page 4 of 10
http://www.biomedcentral.com/1471-2407/13/172time as samples for pharmacokinetic analysis. Cytokine
measurements were determined by Cytometric Bead
Array (CBA; BD Biosciences). Serum of patients were in-
cubated with labeled capture beads and detection reagent
for 3 h in the dark at room temperature and were analyzed
with a flow cytometer (FACSCalibur; BD Biosciences) using
the respective CBA Analysis software (BD Biosciences)
and Bender MedSystems software. Each experiment was
performed in duplicate to ensure for reproducibility of
results, as previously described [31,32].
Natural Killer activity analysis
Blood samples for NK cell activity analysis were
collected before and 2 h after the first and the 2nd, 3rd,
9th and 15th injections. NK cells were isolated with
lymphocytes from blood by density gradient centrifugation
(Unicep, Novamed, Jerusalem) and purified with CD56
coated magnetic microbeads (Miltenyi Biotec). They were
incubated with or without recombinant IL-2 for 40 h, then
incubated in 96-well plates for 4 h with K562 human
leukemia cells or Daudi cells which were used as NK and
LAK target cells (TC), to yield a NK :TC ratio of 10.
NK cytotoxicity was classically calculated as in chrome
test assay.
TLR 4 polymorphism analysis
The analysis of 2 single nucleotide polymorphisms of TLR
TLR4D299G and TLR4T399I was performed as previously
described by Ducloux et al. [33].
Prior to polymorphism analysis, gDNA was extracted
from serum and amplified using the Whole Genome
Amplification method Polymorphisms analysis was
then performed using restriction fragment length poly-
morphism method and direct PCR sequencing for TLR4
(2 polymorphisms).
Statistical analysis
Because of the nature of this study, no formal statistical
analysis was planned. Evaluation of the data consisted
primarily on summary displays (i.e., descriptive statistics
and graphs). Qualitative data were summarized by
frequency and percentages, while quantitative data were
summarized by descriptive statistics.
Results
Patient characteristics
From November 2004 to July 2007, 17 patients were
enrolled. Their characteristics are described in Table 2.
Main tumour type was colon or rectal cancers, followed
by breast cancer and ovarian cancer. All patients were
included after failure of optimal standard treatment,
including chemotherapy which consisted in the majority
(58.8%) of cases in 4 or more lines, according to their
tumor type.Drug delivery
A total of 138 infusions were administered with a median
number of 5 injections (range: 3 to 15). Protocol was
amended after 15 patients have been included, to suppress
dose level 6 and 7 to facilitate patient enrollment. The
investigator had the choice to continue treatment as up
to a total of 15 infusions if a benefit was observed for
the patient.
Number of patients and total of delivered infusions in
each DLs are depicted in Table 1.
The majority of the subjects (82%) received all the
administrations planed in each DL. At DL3 (15 injections
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breast cancer, received only 6 infusions due to a rapid
alteration of her general status in relation to a progressive
disease; at DL 5 (10 injections of 800 μg/m2), a 46-year
-old woman with ovarian cancer and a 68-year-old man
with liver cancer received respectively only 4 and 3 out of
10 OM-174 infusions because of a progressive disease in
the first case and a severe adverse event, bronchospasm,
in the other one.
Safety results
All patients were evaluable for safety analysis. No
haematological disorders were observed after OM-174
administration, in any patient.
Non haematological adverse events are shown in
Table 3, according to treatment cycle. The most frequent
adverse event was flu-like syndrome, reported by 12 of
the 17 patients. However no grade 3 and 4 events were
observed. Chills occurred in 12 patients, associated with
fever in 7 cases. For patient’s convenience, IV acetamino-
phen had to be administered after 68 of 138 (49%)
OM-174 infusions and Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) after 19 (14%) OM-174 infusions to treat
flu-like syndromes.
Gastro-intestinal disorders were seen in 7 patients.
Four of them had nausea or vomiting and 3 diarrhea.
Four patients experienced fatigue and three reported
having headache after OM-174 administration.
All other adverse events, hypertension not requiring
treatment, dizziness, somnolence, and dysphagia, were
graded one and were experienced by a single patient.
Grade 1 hepatic cytolysis and cholestasis were observed
in a patient who had a progressive disease, and it wasTable 3 Incidence of worst grade for most common
drug-related non haematological adverse events per cycle
NCI CTC grading
Adverse Events All grades N (%) G3 N (%) G4 N (%)
Chills 12 (70) - -
Fever 7 (41) - -
Nausea 4 (23) - -
Vomiting 4 (23) - -
Fatigue 4 (23) - -
Headache 3 (17) - -
Diarrhoea 3 (17) - -
High blood pressure 1 (7) - -
Dizziness 1 (7) - -
Somnolence 1 (7) - -
Dysphagia 1 (7) - -
Cholestasis 1 (7) - -
Cytolysis 1 (7) - -
bronchospasm 1 (7) - -concluded that this abnormalities were unlikely related to
the drug.
No death related to the drug was observed during the
study.
Determination of the MTD
All the 17 patients enrolled were evaluable for the
determination of the MTD, but since no DLT was
observed its determination was not feasible.
However, a patient included in the study for progressive
hepatocarcinoma and scheduled to be treated at dose level
5 (10 infusions of 800 μg/m2 of OM-174) experienced a
serious adverse event after the third administration. The
patient exhibited a severe bronchospasm with oxygen
desaturation, hypoxemia immediately at the end of the
treatment. He fully recovered after an IV-infusion of
corticosteroids but did not receive any further adminis-
tration of the study drug. This was not considered as a
dose-limiting toxicity since it was not related to the dose
and was more likely to be of immunological origin, as
patients receiving the next dose of 1000 μg/m2 and the 5
additional patients who received the same dose of
OM-174 (800 μg/m2) for at least five administrations did
not experience such grade 3 or 4 toxicity.
Pharmacokinetics
All 17 patients were evaluable for PK.
After the first IV infusion at the single dose of 600 μg/m2,
OM-174 pharmacokinetic profile showed a Tmax longer
than the end of the infusion, a Cmax reaching 394 ng/ml
and a two phases elimination process (an initial phase
of only a few minutes and a second phase lasting about
22 hr). Clearance and volume of distribution were low,
0.11 L/h (66 mL/hr/m2) and 4.6 L (2643 mL/m2),
respectively. No accumulation occurred at the multiple
dosages of 600 μg/m2 twice a week, whereas a small
accumulation was evidenced for the higher 800 and
1000 μg/m2 dosages.
Cytokines dosage
All patients were evaluable for this analysis. Cytokine
changes induced by OM-174 infusions are summarized
in Table 4. Several profiles were observed. Unlike IL-1β
and IL-12 which were not detectable (data not shown),
IL-8 (Figure 1a) and to a lesser extend IL-10 increased
after each OM-174 injection within same range, whereas
peaks of TNF-α and IL-6 concentrations decreased from
the first to the last injection of OM-174, suggesting
tolerance (Figures 1b and 1c).
Natural killer activity analysis
When all patients with available data were considered,
neither the number nor the activity of NK cells were
increased. Nevertheless in patients receiving 15 injections










IL8 2h 600 2417 54 5000
800 3053 443 5000
1000 1469 1169 1768
IL6 2h 600 461 3 1521
800 1403 150 5000
1000 676 296 1058
IL10 2h 600 42 4 138
800 90 4 326
1000 48 43 52
TNF-α 1h 600 907 4 1446
800 684 4 1970
1000 754 485 1024
IL12 2h 600 12 0 35
800 0 0 11
1000 8 8 9
IL1β 1h 600 34 0 115
800 0 0 0
1000 13 12 14
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was increased compared with baseline value, from
0.67 ± 0.25 × 106 to 2.21 ± 0.17 × 106 NK cells
(p<0.005). Furthermore, patient 17, who received the
highest dose of OM-174 (1000 μg/m2) and the highest
number of injections (15) showed a significant progressive
increase in NK cell activity as OM-174 infusions were
repeated (Figure 2).
TRL 4 polymorphism analysis
All but one (16 out of 17) patients of this cohort
carried the wild type alleles for TLR4D299G and all for
TLR4T399I polymorphisms, making us unable to assess
the relationship between TLR4 polymorphisms and
response to OM-174, either in terms of biological or
clinical response.
Antitumor activity
Responses were assessed by the investigator in every
patient.
One patient with hepatocellular carcinoma who was
withdrawn from the study after the third administration
because of grade 3 toxicity (bronchospam) was not
available for tumor response.
Stabilization of disease was documented in 3 patients
(17%) and seen at DL 3, DL4 and DL8. Characteristics of
these patients are summarized in Table 5. Although no
formal statistics were performed, no trend was observed
for a correlation between disease course and any of thebiological parameters that were assessed in the present
study.
Discussion
Our study strengthens data on the overall very
favourable safety profile of OM-174, as administered for
up to 15 injections as a biweekly infusion and up to
1000 μg/m2 which is the recommended dose. Chills
(70%) and fever (41%) were the most common adverse
advents, with no grade 3 or 4, explaining that the MTD
could not be determined, and were reversible with acet-
aminophen, NSAID or steroid treatments. Furthermore
no increase in severity occurred as injections were
repeated. It might be argued that giving acetaminophen
or NSAIDs to patients with grade 1 or 2 fever might
impair antitumoral effect as it has been suggested that
response to IL-2 plus interferon-alpha might be altered
by acetaminophen in patients with metastatic melanoma
[34]. Nevertheless our patients were included prior to
this report that has never been published as a full paper
and only a trend was suggested. The number of patients
with disease stabilization observed in our study (3) is
too small to allow for an appropriate assessment of the
influence of acetaminophen or NSAIDs use in tumour
response, but it has to be noticed that these 3 patients all
received acetaminophen.
Others adverse events included nauseas, vomiting,
fatigue, headache and diarrhoea and were generally of
mild to moderate intensity. The more severe adverse
event was an episode of bronchospasm which occurred
for a patient with a progressive hepatocarcinoma after
the third infusion of 800 μg/m2.
The safety profile of OM-174 we describe here is similar
to that observed in others studies with other lipids A
[26-28], whether the lipid A was of synthetic origin as
SDZ MRL 953 [26] and ONO-4007 [27], or prepared from
S typhimurium and minnnesota as in the phase I trial
performed by Vosika et al. Similarly to our study, Vosika
et al. described bronchospasm in one patient, considered
as a severe adverse event. In this study another patient
experienced, at the highest dose level (500 μg/m2) a severe
hypotension which was considered by the authors as a
DLT. It has to be noted that we assessed twice higher dose
and number of injections (15 vs. 8) of lipid A than in the
study by Vosika et al [28].
OM-174 PK parameters appeared to be independent
of dose within the dose range of 600 – 1000 μg/m2. A
trend toward higher OM-174 concentrations was observed
when administered doses increased, but the difference was
not significant. OM-174 is a drug with a low systemic
clearance (0.11 L/h) and a small distribution volume
(4.6 L). Our results are in agreement with those of de
Bono et al. [27] who described that the pharmacokinetic
of ONO-4007, another synthetic lipid A analogue,
Figure 1 a Increase of IL-8 concentration after each injection of OM-174 with a peak at second hour, independently of dose of OM-174
and number of injections. Black, doted and white boxes represent the value of the cytokine of interest 1, 2 and 4 hours after the injection of
interest. Analyses were conducted on all 17 patients according to their number of OM-174 injections. 1b and 1c Both concentration of TNF-α
and IL-6 decreased after each injection of OM-174 suggesting a tolerance. The peak of secretion is observed respectively 1 and 2 hours after the
first injection of OM-174 for TNF-α and IL-6. Black, doted and white boxes represent the value of the cytokine of interest 1, 2 and 4 hours after
the injection of interest. Analyses were conducted on all 17 patients according to their number of OM-174 injections.
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Figure 2 Increase of NK activity after each injection of 1000 μg/m2
OM-174 and in association with IL-2.
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with respect to time. ONO-4007 was described to have a
low systemic clearance (approximately 1.3 ml/min) and a
small volume of distribution (5-8 liters) with a long t1/2 of
74-95 h. These data validated the twice weekly administra-
tion protocol. It has previously been reported that shorter
intervals between repeated injection of LPS lead to the
development of LPS tolerance [35] and similar tolerance
might have occurred with Lipid A analogues even if it has
never been studied.
Pharmacodynamic studies showed OM-174 IV-infusion
induced a significant increase in IL-8, IL-10, IL-6 and
TNF-α concentrations. IL-8 and IL-10 concentrations
increased after each OM-174 injection whereas TNF-α
and IL-6 concentrations were highest after the first
OM-174 injection and declined thereafter as OM-174
injections were repeated. This response was not correlated
to the dose of OM-174 and is known as tolerance. The
occurrence of tolerance or host desensitization in animals
and humans administered multiple doses of microbial
products has long been recognized [36]. It was reported
with OM-174 in preclinical studies. In the study by De
Bono et al. [27], an increase in IL-1α, IL-6, and TNF-α
concentration was observed whereas it was not the case
with SDZ MRL 953 in the study by Kiani et al. [26]. Our
study is in partial agreement with both studies as we
observed an increase in TNF-α, IL-6, IL-8 and IL-10, but
not in IL-1β or IL-12. This increase of secretion of TNF-α
is in the same magnitude as that observed with ONO-
4007 (1970 versus 1200 pg/ml), suggesting a similar bio-
logical activity and confirming that OM-174 activates the
TLR4 receptor as has been demonstrated in preclinicalTable 5 Characteristics of patients with stable disease
Nb of patients Age (YEARS) Sex Previous lines of
chemotherapy
DL
Patient 9 60 Male 11 3
Patient 12 62 Male 3 4
Patient 17 57 Male 4 8models. The variations of cytokines secretion could be
due to the dose (from 2 to 125 mg/patient), or adminis-
tration schedules (every day for SDZ MRL 953, every
week for ONO-4007) differences, between the three
clinical assays. However, the best clinical tolerance of
OM-174 makes it a drug of choice for clinical development.
Interestingly, our study also suggests that a sufficient
number of OM-174 injections has to be administered to
reach a biological activity since a trend toward an
increase in NK cells number and activity was observed
only in patients receiving 15 infusions. As only three
patients received 15 infusions these findings deserve
further studies to be confirmed.
As OM-174 has been shown, in mice, to induce TNF-α
production via TLR4 receptors, a family of receptors
which recognized pathogen-associated microbial structure
and are involved in innate immune cell activation and
antitumor immune response inducing tumor cell death
[37], we search for possible mutations that may explain
inter patient variability in terms of biological and clinical
activities. Sixteen out of seventeen patients in our study
carried the wild type suggesting that TLR4 responsiveness
was unaltered in our population. Since no functional
analysis was performed, we cannot formally rule-out a
TLR4-mediated variability in clinical response, but in the
absence of genomic variability this is unlikely to be the case.
However, the finding of TNF secretion after administration
of OM-174 in our study as has been observed in mice
suggested that OM-174 activates TLR4 well.
We did not observed objective tumour responses, as it
was the case in the Vosika [28] or de Bono [27] studies,
but disease stabilisation occurred in 3 patients including
2 patients with colo-rectal carcinoma and one patient
with non-small cell lung carcinoma. As disease stabilisa-
tion was observed at 3 different dose levels including
three different doses and number of infusion, and as no
patients were included in some dose levels, no trend can
be suggested toward the most interesting dose level.
Nevertheless, even if these stabilizers have no significant
value, they deserve our interest on the mechanisms in-
volved, including the induction of cytokine.
It has to be agreed that lipid A analogues, such as
OM-174, do not appear very promising when used alone
in cancer patients. Nevertheless our team has been
working extensively in animal model and our knowledge
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different drugs. Like this, we have shown (unpublished
data) that whereas treatment by either oxaliplatin or
OM-174 alone doesn’t lead to regression of voluminous
peritoneal tumors, induced in BDIX rats by intraperitoneal
injection of syngeneic PROb colon cancer cells. Their
combination induces the disappearance of carcinomatosis.
Conclusion
We have shown that the lipid A analog, OM-174,
administered twice weekly, for up to 15 injections and
1000 μg/m2 offers a predictable and overall favourable
safety profile and good tolerability at biologically active
concentrations. Clinical and biological activities deserve
further experiments, likely in conjunction with chemo-
therapy, as preclinical experiments conducted in our
unit suggest that this combination might be synergistic.
To confirm this hypothesis, we have designed a phase Ib
study in association with a derivate of platine that will
soon be enrolling patients.
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